Alfuzosine Hydrochloride
Alfabax is a medication in the form of a tablet that should be taken orally.
Alfuzosine belongs to a group of medications used to treat prostate gland diseases, called alpha-1-adrenolytics. It causes relaxation of the muscles in the prostate gland and urethra, facilitating urine flow from the bladder.
Alfuzosine is used to treat symptoms of benign prostatic hyperplasia.
Benign Prostatic Hyperplasia
The prostate gland is located below the bladder. The urethra passes through the prostate gland and opens to the outside of the body. In addition to glandular tissue (producing seminal fluid), the prostate gland also contains muscle tissue. Muscle tissue is also found in the urethra. In benign prostatic hyperplasia, the muscle tissue of the prostate gland and urethra becomes tense, causing the urethra to narrow. As a result, urine flow from the bladder is impaired, and symptoms of the lower urinary tract occur.
Acute Urinary Retention
In some patients with benign prostatic hyperplasia, the prostate gland becomes so large that it completely blocks urine flow. This condition is called acute urinary retention.
Before starting Alfabax, discuss with your doctor or pharmacist:
You should consult your doctor if any of the above warnings apply to you or if such a situation has occurred in the past.
Alfuzosine is not intended for use in children.
Tell your doctor or pharmacist about all medications you are currently taking or have recently taken, as well as any medications you plan to take.
This includes medications taken without a prescription.
Some medications may affect the action of other medications or may not be taken at the same time for other reasons.
Alfabax should not be taken if:
You should consult your doctor before taking the medication:
This does not apply. Alfabax is prescribed only to men.
There is no available data on the effect of this medication on the ability to drive or operate machinery. Symptoms such as dizziness or general weakness may occur. This should be taken into account when driving or operating machinery.
This medication contains lactose. If you have previously been diagnosed with intolerance to some sugars, you should consult your doctor before taking the medication.
This medication should always be taken as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
Oral administration.
The usual dose is one tablet per day.
Alfabax will be administered to you by your doctor on the day of catheter insertion.
You should continue taking Alfabax once a day.
You should take one Alfabax tablet after your evening meal. The tablet should be swallowed with a large amount of liquid (e.g., a glass of water). The prolonged-release tablets should not be crushed, chewed, or divided.
The best effect can be achieved by taking the tablet at the same time every day. This also helps remember to take the tablet.
No dose adjustment is necessary in cases of mild or moderate renal impairment, but in cases of severe renal impairment, the doctor will not prescribe this medication.
Alfabax tablets should not be used in patients with hepatic impairment.
However, in cases of mild to moderate hepatic impairment, other products containing alfuzosine in a low dose can be used, according to the appropriate dosing schedule.
Your doctor will inform you about this.
The efficacy of Alfabax has not been established in children aged 2 to 16 years, therefore Alfabax is not recommended for use in children and adolescents (aged 2 to 16 years).
In case of overdose, you should immediately consult your doctor or pharmacist.
It may happen that you forget to take your medication. In such a case, there is no need to take the missed tablet. You can take the prescribed dose of Alfabax the next day.
Do not take a double dose to make up for the missed tablet.
Do not stop or discontinue Alfabax treatment without consulting your doctor first. You should take the tablets as directed and for as long as your doctor has prescribed. Do not stop taking them even if you feel better, as symptoms may return.
If you have any further questions about taking this medication, consult your doctor or pharmacist.
Like all medications, Alfabax can cause side effects, although not everybody gets them.
If you experience any of the following side effects, stop taking Alfabax and immediately consult your doctor or go to the nearest hospital emergency department:
Very Rare (less than 1 in 10,000 people)
Unknown (frequency cannot be estimated from the available data)
Common (less than 1 in 10 people)
Uncommon (less than 1 in 100 people)
Very Rare (less than 1 in 10,000 people)
Unknown (frequency cannot be estimated from the available data)
If you experience any side effects, including those not listed in this package leaflet, please inform your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Medicinal Product Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Aleje Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309.
Website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of this medication.
The medication should be stored out of sight and reach of children.
There are no special storage recommendations.
Do not use this medication after the expiration date stated on the carton and blister pack, after "Expiration Date". The expiration date refers to the last day of the month stated.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medications no longer needed. This will help protect the environment.
The active substance of Alfabax is alfuzosine hydrochloride.
Each prolonged-release tablet contains 10 mg of alfuzosine hydrochloride.
Other ingredients of the medication are: lactose anhydrous, colloidal silicon dioxide (E551), povidone (E1201), talc (E553B), magnesium stearate (E572), hypromellose (E464), hydroxypropyl cellulose (E463).
The tablet has a prolonged release, which means that after administration, the active substance is not released immediately but gradually, and therefore, the medication acts for a longer period.
Alfabax tablets are white to off-white, round, uncoated, biconvex, with smoothed edges, marked 'RY 10' on one side.
Alfabax is available in packs of 30 or 90 tablets.
Not all pack sizes may be marketed.
Ranbaxy (Poland) Sp. z o.o.
ul. Idzikowskiego 16
00-710 Warsaw
tel. 22 642 07 75
Sun Pharmaceutical Industries Europe BV
Polarisavenue 87
2132 JH Hoofddorp
Netherlands
Terapia S.A.
Str. Fabricii Nr. 124
Cluj-Napoca 400 632
Romania
To obtain further information on this medicinal product or the package leaflet in another format, please contact the marketing authorization holder.
France: ALFUZOSINE CRISTERS PHARMA LP 10 mg prolonged-release tablets
Italy: Profuzo
Netherlands: Alfuzosine HC1 SUN 10 mg prolonged-release tablets
United Kingdom (Northern Ireland): Vasran XL 10 mg Prolonged-release Tablets
Date of Package Leaflet Approval:27.05.2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.